工程化新型CD19/CD22双靶点嵌合抗原受体T细胞以增强抗肿瘤活性。
Engineering Novel CD19/CD22 Dual-Target CAR-T Cells for Improved Anti-Tumor Activity.
作者信息
Zeng Wanying, Zhang Qing, Zhu Yangmin, Ou Ruiming, Peng Liang, Wang Baolei, Shen Huijuan, Liu Zhi, Lu Lisheng, Zhang Pumin, Liu Shuang
机构信息
National Center for International Research of Bio-targeting Theranostics, Guangxi Key Laboratory of Bio-targeting Theranostics, Collaborative Innovation Center for Targeting Tumor Diagnosis and Therapy, Guangxi Talent Highland of Bio-targeting Theranostics, Guangxi Medical University, Nanning, China.
Department of Hematology, Guangdong Second Provincial General Hospital, Guangzhou, China.
出版信息
Cancer Invest. 2022 Mar;40(3):282-292. doi: 10.1080/07357907.2021.2005798. Epub 2021 Nov 25.
Despite high remission rates following chimeric antigen receptor T cell (CAR-T) cell therapy in B-cell acute lymphoblastic leukemia (B-ALL), relapse due to loss of the targeted antigen is increasingly recognized as a mechanism of immune escape. We hypothesized that simultaneous targeting of CD19 and CD22 may improve the CAR-T effect. The and leukemia model was established, and the anti-tumor effects of BiCAR-T, CD19 CAR-T, CD22 CAR-T, and LoopCAR6 cells were observed. We found that the BiCAR-T cells showed significant cytotoxicity and . The CD19/CD22 bivalent CAR provides an opportunity to test whether simultaneous targeting may reduce the risk of antigen loss.
尽管嵌合抗原受体T细胞（CAR-T）疗法治疗B细胞急性淋巴细胞白血病（B-ALL）后缓解率很高，但由于靶向抗原丢失导致的复发越来越被认为是一种免疫逃逸机制。我们假设同时靶向CD19和CD22可能会增强CAR-T效应。建立了 白血病模型，并观察了双特异性CAR-T（BiCAR-T）、CD19 CAR-T、CD22 CAR-T和LoopCAR6细胞的抗肿瘤作用。我们发现BiCAR-T细胞表现出显著的细胞毒性 。CD19/CD22二价CAR为测试同时靶向是否可以降低抗原丢失风险提供了机会。
Zotero 插件